Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.1%

Neg 0% Neu 86.1% Pos 0%

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.

Comments

No comments yet. Be the first!